 In this study, it is anticipated to evaluate prospectively 80 patients with AA and low or int-1 risk MDS with IOL, by the traditional methods and MRI T2. Clinical parameters and T2values will be monitored every 12 months for 3 years. Other parameters like clinical follow-ups rate of infection, liver disease, cardiac disorders, endocrine function and other co-morbidities associated with MDSAAs, etc., SF, liver and kidney function, UCG tests will be monitored as well at the interval of every 6 months. At the end of the study, patients will be classified as well chelated groups defined as those received deferasirox 20mgkg or deferoxamine 40 mgkg for more than 255 daysyear or poor chelated groups defined as those received iron chelation therapy dose less than above and compared the differences of their outcome and change of iron status. The investigators aim to give an overview of IOL of patients with AA and low and int-1 risk MDS and their sequelae under different chelation treatment. And the investigators also aim to evaluate the relationship of LIC and T2R2. It is the first and longest prospective clinical trial on AA and low risk MDS and will give us a better understanding of the value of proper chelation treatment for the organ function. 